# Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma

> **NCT03272256** · PHASE1 · COMPLETED · sponsor: **ImmunoMet Therapeutics, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** IM156

## Key facts

- **NCT ID:** NCT03272256
- **Lead sponsor:** ImmunoMet Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2019-12-02
- **Final completion:** 2020-07-28
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03272256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03272256, "Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03272256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*